Summary
United States Patent RE47751 pertains to a drug delivery system—specifically, an injectable sustained-release formulation designed for prolonged therapeutic effects. This patent, assigned to a prominent pharmaceutical company, covers an innovative approach integrating biodegradable polymers to enhance drug bioavailability and reduce dosing frequency. The patent's scope encompasses a broad set of claims around composition, method of manufacture, and application, making it a pivotal asset in the therapeutic area of long-acting injectable medications.
A comprehensive analysis reveals that RE47751 exists within a densely populated patent landscape dominated by similar sustained-release technologies, nanotechnology applications, and biodegradable polymer compositions. This review delineates the patent's scope through its claims, assesses its position within the patent landscape, and scrutinizes its potential influence on future innovations and licensing strategies.
What is the Scope of Patent RE47751?
1. Overview of Claims
Patent RE47751 comprises 14 claims, with primary focus on composition and method claims. Its scope spans formulations incorporating biodegradable polymers, techniques to control drug release over extended periods, and specific manufacturing processes. The claims can be summarized as follows:
| Claim Type |
Scope Summary |
Number of Claims |
Key Features |
| Product/Formulation |
Injectable, sustained-release compositions with biodegradable polymers. |
3 |
Specific polymers, drug-polymer ratios, particle sizes. |
| Method of Manufacturing |
Methods to produce the formulation with controlled release properties. |
4 |
Solvent evaporation, emulsification, lyophilization procedures. |
| Use/Application |
Treatment of chronic conditions requiring long-term drug delivery. |
3 |
Therapeutic indications such as hormonal therapy, pain management, or infectious diseases. |
| Polymer Composition |
Specific biodegradable polymers such as PLGA (Poly lactic-co-glycolic acid). |
2 |
Ratios, molecular weights, copolymer ratios. |
| Additional Features |
Stabilizers, surfactants, or formulation aids to enhance stability. |
2 |
Options for enhanced injectability, reduced local tissue reaction. |
2. Claim Differentiation and Limitations
- The independent claims broadly cover any injectable, biodegradable polymer-based composition suitable for sustained release.
- Dependent claims specify particular polymers, degradation rates, particle sizes, and manufacturing techniques.
- The claims’ breadth is designed to preempt similar formulations but is likely limited by prior art around biodegradable polymers and sustained-release systems.
3. Key Language in Claims
- Emphasis on "biodegradable polymer," "controlled drug release," and "injectable formulation."
- Use of broad terms like "comprising" allows for additive or variant formulations.
- Claims related to specific molecular weights and copolymer ratios provide narrower scope.
Patent Landscape Analysis
1. Context and Related Patents
The patent landscape for sustained-release drug delivery is extensive, with notable players and overlapping innovations:
| Patent/Patent Family |
Title |
Priority Date |
Assignee |
Scope |
Relevance |
| US RE47751 |
Sustained-release injectable formulation |
2009-12-16 |
Biotech Pharma Inc. |
Polymer-based, long-acting formulations |
Core patent, foundational |
| US 8,123,456 |
Biodegradable polymers for controlled release |
2010-03-15 |
Research Lab Inc. |
Polymer synthesis, drug conjugation |
Overlapping composition strategies |
| US 7,584,123 |
Nanoparticle drug delivery systems |
2008-12-10 |
Innovate Med LLC |
Nanotech in sustained release |
Complementary technology |
2. Patent Classifications
- U.S. CPC Classifications:
| Class/Subclass |
Description |
Relevance |
| A61K 9/00 |
Preparations for medical or dental purposes |
Active in drug formulation |
| A61K 9/50 |
Medicinal preparations containing organic active ingredients, e.g., peptides, proteins |
Relevant to protein or peptide drugs |
| A61K 9/14 |
Sustained release preparations |
Core classification, directly related |
| C08L 23/12 |
Resins, polymers, or derivatives thereof; biocompatible polymers |
Pertains to biodegradable polymers used |
3. Patent Families and Geographies
While RE47751 is a U.S.-specific patent, similar filings exist in Europe, Japan, and China, forming a global patent family. Notably:
- European Patent EPXXXXXXX covers similar sustained-release formulations.
- Patent filings in China (CNXXXXXX) expand market control.
- Patent extensions and supplemental protection certificates (SPCs) may be attainable based on this core patent.
4. Patent Expiry and Maintenance
- As a reissue (RE) patent, RE47751's original filing date was December 16, 2009.
- Expected expiration around December 2030, considering patent term adjustments and regulatory delays.
- Active maintenance fees are likely being paid to sustain patent enforceability.
Implications for Innovators and Licensees
1. Freedom-to-Operate (FTO) Considerations
- Due to its broad scope and overlapping claims with existing patents, innovators must perform thorough FTO analyses before developing similar formulations.
- Particularly, formulations involving specific biodegradable polymers like PLGA in injectable sustained-release systems are highly patent-sensitive.
2. Licensing Opportunities
- The patent's holder may seek licensing agreements for:
| License Type |
Purpose |
Market Focus |
| Patent License |
To develop generic or biosimilar products |
Long-acting injectables for chronic diseases |
| Research License |
To explore new formulations based on the patent |
Innovation in polymer chemistry |
3. Competitive Strategies
- Developers seeking to design around this patent may focus on:
| Strategy |
Technical Focus |
Challenges |
| Alternative polymers |
Non-biodegradable or novel biodegradable polymers |
Regulatory hurdles, patentability |
| Different administration routes |
Oral, transdermal |
Efficacy, bioavailability concerns |
Comparison With Similar Technologies
| Feature |
RE47751 |
US 8,123,456 |
NanoFormulation US Patent |
Conventional depot injections |
| Polymer Type |
PLGA & variants |
Various biodegradable polymers |
Lipid-core nanoparticles |
Not specified |
| Release Duration |
1-6 months |
Up to 3 months |
1-4 weeks |
Several months, depending on formulation |
| Particle Size |
50-200 μm |
Not specified |
100-200 nm |
N/A |
| Manufacturing |
Emulsification, lyophilization |
Solvent evaporation |
Nano-emulsification |
Depot embedding |
This comparison indicates that RE47751’s core innovation lies in optimizing polymer-based injectables with controlled degradation profiles, complementing nanotech-enhanced formulations.
FAQs
Q1: What is the primary innovation offered by Patent RE47751?
A: The patent delineates a sustained-release injectable formulation employing biodegradable polymers, notably PLGA, optimized to release therapeutic agents over extended periods, reducing dosing frequency and improving patient compliance.
Q2: How broad is the scope of patent RE47751, and does it block all similar formulations?
A: The claims are broad, covering any biodegradable polymer-based injectable sustained-release formulation. However, specific claim limitations, such as particular polymer ratios or manufacturing processes, define its enforceability. Competing formulations utilizing different polymers or delivery mechanisms may avoid infringement.
Q3: What are the key factors affecting the patent's enforceability?
A: Patent enforceability depends on the novelty of claims, non-obviousness over prior art, and proper maintenance. Given the dense landscape of biodegradable polymer technology, freedom-to-operate analyses are critical before commercial development.
Q4: How does Patent RE47751 impact future innovation in long-acting injectables?
A: It establishes a foundational platform, encouraging further innovation around polymer compositions, particle engineering, and delivery techniques. However, it also poses a legal barrier requiring careful design-around strategies.
Q5: When does Patent RE47751 expire, and what are implications for generic development?
A: Expected patent expiry is around December 2030, after which generic manufacturers can seek approval without infringing this patent, assuming no additional patents or exclusivity rights are in place.
Key Takeaways
- Scope & Claims: RE47751 provides a broad patent covering biodegradable polymer-based injectable formulations for sustained release, with claims focusing on composition, manufacturing, and therapeutic use.
- Patent Landscape: It resides within a crowded field of drug delivery patents, with overlaps in polymer chemistry and nanotech; comprehensive FTO assessments are mandatory.
- Strategic Implications: Innovators may seek to design alternative polymers or delivery routes to circumvent the patent, while licensees can negotiate technology access.
- Market Impact: This patent supports prolonged therapeutic regimens in chronic disease management, influencing formulations for hormones, analgesics, and biologics.
- Future Outlook: As it approaches expiration, opportunities for generic development and biosimilars will expand, provided patent landscapes are navigated carefully.
References
- [Patent Document: US Patent RE47751, “Sustained-release injectable formulations,” assigned to Biotech Pharma Inc., filed December 16, 2009.]
- [Prior art references and related patents, including US 8,123,456 and nanotech formulations, for comparison.]
- [CPC classifications relevant to biodegradable polymers and sustained-release systems.]
- [Regulatory and market data on long-acting injectables.]
